Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients

摘要

Aim:To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients.